Risk of subsequent cutaneous malignancy in patients with prior melanoma: A systematic review and meta-analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 6, 2015, Pages 1053-1062

  Van Der Leest, R J T ^a   Flohil, S C ^a   Arends, L R ^a,b   De Vries, E ^a   Nijsten, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL CARCINOMA; CANCER RISK; CUTANEOUS MELANOMA; DYSPLASTIC NEVUS; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; MULTIPLE CANCER; NONHUMAN; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SQUAMOUS CELL CARCINOMA; STANDARDIZED INCIDENCE RATIO; SYSTEMATIC REVIEW; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; INCIDENCE; MELANOMA; META ANALYSIS; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT; SEX DIFFERENCE; SKIN NEOPLASMS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; INCIDENCE; MELANOMA; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT; SEX FACTORS; SKIN NEOPLASMS;

EID: 84929655903     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12887     Document Type: Review

References (45)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F,. A systematic review of worldwide incidence of non-melanoma skin cancer. Br J Dermatol 2012; 166: 1069-1080.
2. Erdmann F, Lortet-Tieulent J, Schuz J, et al,. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk? Int J Cancer 2013; 132: 385-400.
3. Flohil SC, van der Leest RJ, Arends LR, de Vries E, Nijsten T,. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer 2013; 49: 2365-2375.
4. Hollestein LM, van den Akker SA, Nijsten T, et al,. Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012; 23: 524-530.
5. Baade P, Meng X, Youlden D, Aitken J, Youl P,. Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006. Int J Cancer 2012; 130: 170-178.
6. Murali R, Goumas C, Kricker A, et al,. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol 2012; 19: 1024-1033.
7. Francken AB, Bastiaannet E, Hoekstra HJ,. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 2005; 6: 608-621.
8. Gudbjartsson DF, Sulem P, Stacey SN, et al,. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40: 886-891.
9. Wehner MR, Shive ML, Chren MM, et al,. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345: e5909.
10. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45-60.
11. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41: 2040-2059.
12. Khalesi M, Whiteman DC, Tran B, et al,. A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol 2013; 37: 534-543.
13. Moher D, Liberati A, Tetzlaff J, Altman DG,; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
14. Wells GA, Shea B, O'Connell D, et al,. The Newcastla-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. [WWW document] URL http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (last accessed: 26 February 2014).
15. Aung K, Htay T,. Thiazide diuretics and the risk of hip fracture. Cochrane Database Syst Rev 2011; 10: CD005185.
16. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
18. van Houwelingen HC, Arends LR, Stijnen T,. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002; 21: 589-624.
19. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
20. Ray MC, Gately LE, Krementz ET,. Incidence of multiple primary malignant melanomas (MPM). Clin Res 1985; 33: A457-A.
21. Salava A, Ranki A, Saksela O,. Risk for a second primary melanoma in patients with a history of melanoma and multiple melanocytic nevi: a 5 year follow up study. J Invest Dermatol 2010; 130: S99.
22. Savoia P, Quaglino P, Verrone A, Bernengo MG,. Multiple primary melanomas: analysis of 49 cases. Melanoma Res 1998; 8: 361-366.
23. Schoellhammer HF, Torisu-Itakura H, Huynh Y, et al,. Second primary melanoma: risk factors, histopathologic features, and survival. J Clin Oncol 2009; 27: 9073.
24. Titus-Ernstoff L, Perry AE, Spencer SK, et al,. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol 2006; 142: 433-438.
25. Wendt J, Schanab O, Binder M, Pehamberger H, Okamoto I,. Factors contributing to subsequent melanoma in a central European cohort. Melanoma Res 2010; June 2011-Volume 21-e-Supplement Abstracts of the 7th European Association of Dermato-Oncology Congress (EADO) Nantes, France.
26. Marghoob AA, Slade J, Kopf AW, et al,. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol 1996; 135: 704-711.
27. Siskind V, Hughes MC, Palmer JM, et al,. Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol 2011; 131: 461-467.
28. Uliasz A, Lebwohl M,. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol 2007; 46: 575-577.
29. Helm KF, Bittenbender S, Localio R,. Coexisting malignancies in patients with malignant melanoma. Arch Dermatol 1996; 132: 471-472.
30. de Giorgi V, Rossari S, Papi F, et al,. Risk of second primary melanoma: how should be long follow-up? Ratio of observed and expected cases. J Eur Acad Dermatol Venereol 2012; 26: 1454-1455.
31. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M,. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001; 145: 981-985.
32. Stacey SN, Gudbjartsson DF, Sulem P, et al,. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 2008; 40: 1313-1318.
33. Rosso S, Zanetti R, Martinez C, et al,. The multicentre south European study 'Helios'. II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br J Cancer 1996; 73: 1447-1454.
34. Kricker A, Armstrong BK, English DR, Heenan PJ,. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer 1995; 60: 489-494.
35. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41: 28-44.
36. Madan V, Lear JT, Szeimies RM,. Non-melanoma skin cancer. Lancet 2010; 375: 673-685.
37. Hay RJ, Johns NE, Williams HC, et al,. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2014; 134: 1527-1534.
38. United States Preventative Services Task Force. skincanrs.pdf. http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/skin-cancer-screening (last accessed: 13 November 2014).
39. Holterhues C, van de Poll-Franse LV, de Vries E, Neumann HA, Nijsten TE,. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 patients from the general Dutch population. J Eur Acad Dermatol Venereol 2012; 26: 1389-1395.
40. Glusac EJ,. The melanoma 'epidemic': lessons from prostate cancer. J Cutan Pathol 2012; 39: 17-20.
41. Mols F, Holterhues C, Nijsten T, van de Poll-Franse LV,. Personality is associated with health status and impact of cancer among melanoma survivors. Eur J Cancer 2010; 46: 573-580.
42. Flohil SC, Proby CM, Forrest AD, et al,. Basal cell carcinomas without histological confirmation and their treatment: an audit in four European regions. Br J Dermatol 2012; 167 (Suppl. 2): 22-28.
43. Boyle P, Parkin DM,. Chapter 11: statistical methods for registries. In Cancer Registration: Principles and Methods Edited by: O.M. Jensen, D.M. Parkin, R. MacLennan, C.S. Muir and R.G. Skeet (IARC Scientific Publication No 95). International Agency for Research on Cancer, Lyone, France, 1991: 126-158.
44. Egger M, Smith GD, Sterne JA,. Uses and abuses of meta-analysis. Clin Med 2001; 1: 478-484.
45. Ahmed I, Sutton AJ, Riley RD,. Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey. BMJ 2012; 344: d7762.